Loïc Louvet

Loïc Louvet

Auto-generated profile, based on publicly available information

Loïc Louvet

UR UPJV 7517 MP3CV, CURS, University of Picardie Jules Verne, Amiens, 80054 France

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2026 in Calcified Tissue International
Verified
Journal Article
Open access
PDF file
LPLauter Eston Pelepenko
Lauter Eston Pelepenko
JBJoaquim Barreto
Joaquim Barreto
MMMarília P. Martins
Marília P. Martins
PCPedro B. Chiteculo
Pedro B. Chiteculo
JCJessica M. Camargo
Jessica M. Camargo
RORodrigo Bueno de Oliveira
Rodrigo Bueno de Oliveira
The effects of gliflozins on bones of CKD patients on dialysis are unknown. Recently, SGLT2 expression in bone tissue of patients with CKD has been reported. We hypothesized that dapagliflozin may act in bone cells and modulate the Klotho-FGF23 axis. This study analyzed the effects of dapagliflozin on serum bone biomarkers and related outcomes. In this predefined post-hoc analysis of a previous RCT, patients on dialysis received (1:1) dapagliflozin 10 mg daily or standard care for 24 weeks. The primary endpoint was the change from baseline in serum Klotho and FGF23 levels, compared by ranked analysis of covariance, adjusted by baseline. Exploratory analyses evaluated calcium, phosphate, PTH, bone-ALP, TRAP-5b, DKK1, sclerostin, and bone proteins. Bone fractures, osteopenia, and osteoporosis were outcomes of interest. Seventy-nine patients were included in this analysis (Control N=40 and Dapagliflozin N=39). At baseline, no significant differences in biomarkers were observed. The prevalence of osteopenia and osteoporosis was 73% and 43% ( p = 0.60 and p = 1.00), respectively. After 24 weeks, the between-group analysis of the change from baseline (delta), adjusted by baseline, revealed a significant difference in serum Klotho [19.1 (− 38.9–86.3) pg/mL, Control group; − 29.1 (− 94.1–43.9) pg/mL, Dapagliflozin group (F:4.946, p = 0.03)], but not on FGF23 levels, nor other biomarkers. The follow-up prevalences of osteopenia and osteoporosis were 70% and 48% ( p = 0.27 and p = 0.61, respectively). No bone fractures were observed. Dapagliflozin use over 24 weeks in patients on dialysis was independently associated with lowered serum Klotho levels, without effects in other bone biomarkers or related outcomes.

4 November 2026 in Kidney360
Verified
Journal Article
Open access
GBGérémy Blot
Gérémy Blot
QBQuentin de Berny
Quentin de Berny
LLLoïc Louvet
Loïc Louvet
LVLudivine Vasseur
Ludivine Vasseur
CACarine Avondo
Carine Avondo
LHLucie Hénaut
Lucie Hénaut
Background: Calcific aortic valve disease (CAVD) is prevalent in chronic kidney disease (CKD), yet no pharmacological therapies exist. Preclinical models rarely incorporate CKD–mineral and bone disorder (CKD-MBD) features, limiting translational potential. We aimed to develop a comprehensive preclinical approach to study CKD-associated CAVD, suitable for standardized assessment of therapies on valvular, cardiac, vascular, and skeletal outcomes. Methods: Eight-week-old male Sprague Dawley rats were assigned to a control group (n=17) fed standard chow or an adenine-phosphate group (AP, n=21) fed chow supplemented with 0.3% adenine and 1.15% phosphate. Diets were enriched with 20% lactose and 19% casein to facilitate phosphate absorption and calcium solubility. Cardiac function was evaluated by echocardiography at baseline, week 5, and 9, with concurrent blood sampling. Aortic valve (AV) calcification was assessed by Alizarin Red and Osteosense staining, and aortic calcium quantified using O-Cresolphthalein Complexone. Gene expression in the aorta and left ventricle (LV) was analyzed by RNA-seq at week 9, and bone microarchitecture assessed by micro-CT. Results: AP rats showed progressive increases in serum creatinine, calcium-phosphorus product, and uremic toxins. By week 9, they exhibited significant AV calcification, with reduced valve area and cusp separation. Relative wall thickness and LV histology were preserved, though transcriptomics revealed early priming toward inflammation and fibrosis. AP rats’ aortas showed calcification, osteogenic features and reduced systolic expansion. Bone analysis revealed cortical thinning and increased porosity, while trabecular bone showed reduced trabecular number, increased trabecular spacing, and compensatory thickening. Together with elevated PTH and FGF23 levels, these changes suggest high bone turnover due to secondary hyperparathyroidism and are correlated with the extent of AV calcification. Conclusions: These results underscore the model’s translational relevance, addressing multiple facets of CKD-MBD and supporting its use for preclinical screening of novel therapies targeting CKD-associated cardiovascular calcification.